Author:
Li Genpeng,Chen Wenjie,Gong Yanping,Wei Tao,Gong Rixiang,Zhu Jingqiang,Li Zhihui,Lei Jianyong
Abstract
Papillary thyroid carcinoma (PTC) has a favorable prognosis, but a fraction of cases show progressive behaviors, becoming radioiodine refractory (RAIR) PTC. To explore circulating exosomal microRNAs (miRNAs) associated with RAIR PTC, the miRNA profiles in exosomes from parental and induced RAIR cell lines were firstly identified with a next-generation sequencing technique. The Na+/I− symporter (NIS) related miRNAs were then validated by quantitative real-time PCR (qRT-PCR) in plasma of PTC patients with non-131I-avid metastases and those with 131I-avid metastases. The regulation of exosomal miRNAs on NIS were also verified. We identified that miR-1296-5p, upregulation in exosomes from RAIR cell lines, and the plasma of patients with RAIR PTC achieved the largest areas under the curve (AUC) of 0.911 and that it is an independent risk factor for RAIR PTC. In addition, miR-1296-5p was abundantly detected in the tissue of RAIR PTC and can directly target downstream gene of NIS. Taken together, our findings suggested that circulating exosomal miRNAs, particularly miR-1296-5p, may be involved in the pathogenesis of RAIR PTC by directly targeting NIS.
Funder
National Natural Science Foundation of China
Sichuan Province Science and Technology Project of China
1·3·5 project for disciplines of excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University
Fundamental Research Funds for the Central Universities
Support Program of Chengdu Science and Technology Agency
Key Research Project of Social Development Department of Sichuan Science and Technology Agency
Popular Application Project of Health Commission of Sichuan Province
Reference38 articles.
1. Trends in Thyroid Surgery and Guideline-Concordant Care in the United States, 2007–2018;Toumi;Thyroid,2021
2. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?;Haugen;Cancer,2017
3. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer;Koehler;Thyroid,2021
4. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer;Brose;J. Clin. Endocrinol. Metab.,2022
5. Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study;Ballal;Thyroid,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献